CJC-1295 (no DAC) — wholesale 10-vial kits

Research context

Mod GRF 1-29 sits in the same structure–activity tradition as the rest of the GHRH-analog family: systematic alanine and Aib scans of hGHRH(1-29)NH₂ identified individual positions, position 15 among them, where substitution raises in-vitro potency relative to the native hormone, while other positions lose activity altogether (Cervini et al., Journal of Medicinal Chemistry, 1998). The four changes carried by this analog combine that affinity-raising substitution with three stability substitutions.

The first 29 residues of GHRH carry its receptor activity, but the native fragment is inactivated three ways: dipeptidyl peptidase-4 cleaves the Ala2–Asp3 bond, Asn8 rearranges to Asp and β-Asp through an aminosuccinimide intermediate, and Met27 oxidizes (Campbell et al., Peptides, 1994). Mod GRF 1-29 answers each of those routes with D-Ala2, Gln8 and Leu27, and adds Ala15 in place of Gly15, a substitution reported to raise receptor-binding affinity. The result is a more stable GHRH-receptor agonist that is still short-acting.

The name causes confusion. "CJC-1295" originally described ConjuChem's drug affinity complex (DAC) version: the same tetrasubstituted GRF(1-29) with an added C-terminal lysine carrying an Nε-3-maleimidopropionamide group, which forms a covalent bond with the free thiol of Cys34 on serum albumin in the body. In rats, Western blots showed that conjugate on the albumin band within 15 minutes, and it was still measurable in plasma beyond 72 hours (Jetté et al., Endocrinology, 2005). The identity table on this page uses PubChem CID 56841945, the no-DAC tetrasubstituted peptide; CID 91971820 is the DAC form. The product sold here is the no-DAC peptide, and each lot's LC-MS mass on the COA confirms which molecule it is.

In research, Mod GRF 1-29 is used to study GHRH-receptor signaling in pituitary somatotroph models, the pulsatility of growth-hormone release, and the interaction between GHRH-receptor and ghrelin-receptor (GHS-R1a) agonists, which is why it is often paired with ipamorelin. Because the DAC form stays tethered to albumin while the no-DAC peptide is cleared quickly, the two are not interchangeable in pulsatility work; the DAC form has its own published pharmacology, and other half-life-extension strategies for GHRH, such as PEGylation, have been characterized in parallel.

U.S. regulatory status: CJC-1295 is not an FDA-approved drug. It was nominated for FDA's 503A compounding bulks list and placed in Category 2 of the interim policy; FDA's current page lists it among the substances whose nominations were withdrawn by the nominators, and FDA's published rationale cited immunogenicity risk for certain routes, peptide-related impurity and characterization complexity, and limited clinical data. WholesalePeptide.us supplies it only for in-vitro, analytical and preclinical laboratory research.

Analytically, Mod GRF 1-29 is a 29-residue amidated peptide with one D-amino acid, so it resolves well on RP-HPLC; the main related substances are deletion sequences from synthesis and slow glutamine deamidation under poor storage. The COA's LC-MS mass is the decisive check, because the DAC form is a few hundred daltons heavier. Labs studying GHRH / GHS-R1a synergy usually order it together with ipamorelin, either as separate kits or as the pre-blended kit, and both count toward the same wholesale tier.

Research areas

• GHRH receptor agonism
• Pituitary somatotroph cell models
• Growth-hormone pulsatility studies
• GHRH / GHS-R1a co-agonist pharmacology
• Peptide stability engineering (DPP-4, deamidation and oxidation resistance)
• Albumin bioconjugation chemistry for half-life extension (DAC)

U.S. regulatory status of the compound (as an active ingredient): Not approved by the FDA. The material sold here is a research reference chemical, not a drug product.

Handling and storage

• Store lyophilized vials at −20 °C, sealed, protected from light and moisture.
• Let the vial reach room temperature before opening to limit condensation on the powder.
• Reconstitute in a sterile buffer appropriate to the assay, following your lab's SOP.
• Aliquot reconstituted material and freeze once; avoid repeated freeze–thaw.